Table 3.
Comparison of age, duration of disease, final dose, frequency of administration of canakinumab and number of adjustments (dose and/or frequency) performed during 12 months in patients with MWS and CINCA
| Muckle-Wells (6 patients)1 |
CINCA (7 patients) |
P-value2 | |
|---|---|---|---|
| Age, years, median (range) | 13.6 (10.7, 23.7) | 15 (8.7, 38.0) | 0.56* |
| Disease duration, median, years (range) | 13,6 (3.0, 23.2) | 15 (8.7, 38.0) | 0.61* |
| Dose, mg/kg, median (range) | 2.15 (2.0, 3.7) | 3.7 (2.0, 5.9) | 0.16* |
| Frequency, weeks, median (range) | 8 (6, 10) | 6 (4, 8) | 0.03 |
| Adjustments/year, number | 2 | 9 | 0.05 |
1Includes two patients with a Muckle-Wells syndrome (MWS)/chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; 2Mann-Whitney U-test, *not significant.